The U.S. Food and Drug Administration has issued emergency use authorization (EUA) for the following outpatient medications, listed below in order of treatment preference as recommended by the NIH.
Patients with a test-confirmed COVID-19 diagnosis and are experiencing symptoms, may be eligible for an outpatient treatment option, based on when their symptoms started.
NOTE treatments are only viable if given within number of days from symptom onset. Paxlovid and within 5 days; and remdesivir within 7 days. Learn more about these treatments at fda.gov.
Paxlovid treatment for eligible patients. This is an oral treatment and it requires a prescription to the pharmacy. Reference the Paxlovid EUA fact sheet for dosing information, contraindications, and drug-drug interactions.
Check Paxlovid drug-drug interactions with Paxlovid. This may be done at COVID-19 Drug Interactions by LiverPool
If patient is eligible, there is no contraindications, and drug-interactions are manageable, send prescription electronically to GLFHC Pharmacy at 34 Haverhill St in Lawrence, MA or patient’s preferred pharmacy if available.
Remdesivir treatment for eligible patients not able to receive Paxlovid. Given as an intravenous infusion over three consecutive days.
At this time, we do not have this treatment available at GLFHC.
See here for information for providers about therapeutic treatment access
: Monoclonal antibody therapy given as a one-time intravenous injection. It is active in vitro against omicron sub-variants, but there are no clinical efficacy data available. Recommended for use when preferred treatment options are not available, feasible to use, or clinically appropriate.
GLFHC providers can place an internal referral order for via the electronic medical record or complete form below.
Outside providers not affiliated with GLFHC
For patients 12+, submit form below. A member of the COVID Therapeutics Team will contact the patient to schedule an appointment if qualifies.
Patient requiring oxygen therapy and/or respiratory support due to COVID-19,
requiring an increase in baseline oxygen flow rate, and/or respiratory support due to COVID-19 and are on chronic oxygen therapy
is an oral treatment for mild-to-moderate COVID-19 in adults who are at high risk for progression to severe COVID-19, including hospitalization or death, and for whom alternative COVID-19 treatment options authorized by the FDA are not accessible or clinically appropriate. Reference the Molnupiravir Fact Sheet for Healthcare Providers for dosing information and contraindications.
If patient is eligible and there is no contraindications, send prescription electronically to GLFHC Pharmacy at 34 Haverhill St in Lawrence, MA or patient’s preferred pharmacy if available.
GLFHC Locations, Hours and Phone Numbers
GLFHC Pharmacy (for oral treatment options) – Located at Greater Lawrence Family Health Center
34 Haverhill St. Lawrence, MA 01841
Hours: Mon-Thu 8:30 am-9 pm; Fri 9 am-9 pm; Sat-Sun 9 am-5 pm
GLFHC Infusion Clinic (for IV treatment options) – Located at Marston Medical Center
25 Marston St, Suite 101 (1st floor) Lawrence, MA 01841
Hours: Mon-Sat 8 am to 6 pm